Difference between revisions of "Trebananib (AMG-386)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
| + | '''In clinical trials''' | ||
==General information== | ==General information== | ||
Class/mechanism: Selective angiopoietin 1/2-neutralizing peptibody, interferes with interactions of angiopoietins and Tie2 receptors, inhibiting angiogenesis.<ref>[http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/14033 AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors]</ref> | Class/mechanism: Selective angiopoietin 1/2-neutralizing peptibody, interferes with interactions of angiopoietins and Tie2 receptors, inhibiting angiogenesis.<ref>[http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/14033 AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors]</ref> | ||
Revision as of 02:46, 24 December 2011
In clinical trials
General information
Class/mechanism: Selective angiopoietin 1/2-neutralizing peptibody, interferes with interactions of angiopoietins and Tie2 receptors, inhibiting angiogenesis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.